GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » LT-Debt-to-Total-Asset

Sophia Genetics (Sophia Genetics) LT-Debt-to-Total-Asset : 0.08 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sophia Genetics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.08.

Sophia Genetics's long-term debt to total assets ratio increased from Mar. 2023 (0.06) to Mar. 2024 (0.08). It may suggest that Sophia Genetics is progressively becoming more dependent on debt to grow their business.


Sophia Genetics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Sophia Genetics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics LT-Debt-to-Total-Asset Chart

Sophia Genetics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.10 0.03 0.04 0.06 0.08

Sophia Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.07 0.07 0.08 0.08

Sophia Genetics LT-Debt-to-Total-Asset Calculation

Sophia Genetics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=15.673/206.156
=0.08

Sophia Genetics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=14.738/180.258
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sophia Genetics  (NAS:SOPH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Sophia Genetics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Sophia Genetics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophia Genetics (Sophia Genetics) Business Description

Traded in Other Exchanges
Address
Rue du Centre 172, Saint-Sulpice, CHE, CH-1025
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.